{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_012",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:d4a5d542d8636c3b09cb1092d9f6ee506b674e9f65c6b66f62b503a44e6d274c",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:00:33.473776",
  "content": "## 2024-05-20 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 103\n- Active: 99\n- Screen Failures Cumulative: 15\n- Withdrawals Cumulative: 4\n\n### Enrollment by Dose Group\n- Low Dose: 24\n- Mid Dose: 26\n- High Dose: 26\n- Placebo: 27\n\n### Immunogenicity By Group\n- Low Dose\n  - IgG Titer (GMU) Mean: 75.3\n  - IgG Titer (GMU) SD: 6.0\n  - IgM Titer (GMU) Mean: 16.4\n  - IgM Titer (GMU) SD: 4.0\n  - Neutralizing Ab ID50 Mean: 122.3\n  - Neutralizing Ab ID50 SD: 10.0\n  - CD4 Response (SFC/10^6) Mean: 199.0\n  - CD4 Response (SFC/10^6) SD: 15.0\n  - CD8 Response (SFC/10^6) Mean: 130.0\n  - CD8 Response (SFC/10^6) SD: 11.0\n  - Seroconversion Percentage: 33.6\n- Mid Dose\n  - IgG Titer (GMU) Mean: 130.2\n  - IgG Titer (GMU) SD: 9.6\n  - IgM Titer (GMU) Mean: 30.3\n  - IgM Titer (GMU) SD: 6.4\n  - Neutralizing Ab ID50 Mean: 211.4\n  - Neutralizing Ab ID50 SD: 16.0\n  - CD4 Response (SFC/10^6) Mean: 317.0\n  - CD4 Response (SFC/10^6) SD: 24.0\n  - CD8 Response (SFC/10^6) Mean: 216.0\n  - CD8 Response (SFC/10^6) SD: 18.0\n  - Seroconversion Percentage: 48.7\n- High Dose\n  - IgG Titer (GMU) Mean: 180.8\n  - IgG Titer (GMU) SD: 13.2\n  - IgM Titer (GMU) Mean: 38.6\n  - IgM Titer (GMU) SD: 8.8\n  - Neutralizing Ab ID50 Mean: 276.6\n  - Neutralizing Ab ID50 SD: 22.0\n  - CD4 Response (SFC/10^6) Mean: 420.0\n  - CD4 Response (SFC/10^6) SD: 33.0\n  - CD8 Response (SFC/10^6) Mean: 298.0\n  - CD8 Response (SFC/10^6) SD: 24.0\n  - Seroconversion Percentage: 75.0\n- Placebo\n  - IgG Titer (GMU) Mean: 18.4\n  - IgG Titer (GMU) SD: 1.2\n  - IgM Titer (GMU) Mean: 6.2\n  - IgM Titer (GMU) SD: 0.8\n  - Neutralizing Ab ID50 Mean: 32.8\n  - Neutralizing Ab ID50 SD: 2.0\n  - CD4 Response (SFC/10^6) Mean: 33.0\n  - CD4 Response (SFC/10^6) SD: 3.0\n  - CD8 Response (SFC/10^6) Mean: 23.0\n  - CD8 Response (SFC/10^6) SD: 2.0\n  - Seroconversion Percentage: 4.0\n\n### Injection Site Reactions\n- Pain Percentage: 49.7\n- Erythema Percentage: 12.1\n- Swelling Percentage: 14.6\n- Induration Percentage: 7.5\n- Mean Pain Duration (Hours): 35.1\n\n### Systemic Reactogenicity\n- Fever Percentage: 15.1\n- Fatigue Percentage: 23.5\n- Myalgia Percentage: 31.6\n- Headache Percentage: 22.5\n- Chills Percentage: 10.3\n\n### Safety Labs\n- WBC (K) Mean: 6.1\n- WBC (K) SD: 1.1\n- Lymphocyte Percentage Mean: 29.2\n- Lymphocyte Percentage SD: 7.9\n- Neutrophil Percentage Mean: 45.1\n- Neutrophil Percentage SD: 6.7\n- Platelets (K) Mean: 246\n- Platelets (K) SD: 39\n- CRP (mg/L) Mean: 5.5\n- CRP (mg/L) SD: 0.9\n- Hemoglobin (g/dL) Mean: 13.6\n- Hemoglobin (g/dL) SD: 1.5\n\n### Adverse Events\n- AE ID: VI-AE-1235, Description: myalgia, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: high_dose\n- AE ID: VI-AE-1270, Description: malaise, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n\n### Events\n- Reactogenicity diary card collection rate: 94%\n- Vaccination day 2: 19 subjects received scheduled dose\n\n### Notes\n- Week 12: Immunogenicity assessments on schedule. 103 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 12,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}